

CRF Errors Corrected by the STIC Systems Branch

Serial Number: 09/852,424DF Processing Date: 10-25-01 #1
Edited by: M. Spencer
Verified by: _____ (STIC staff)09/0
1023 Changed a file from non-ASCII to ASCII Changed the margins in cases where the sequence text was "wrapped" down to the next line. Edited a format error in the Current Application Data section, specifically: Edited the Current Application Data section with the actual current number. The number inputted by the applicant was the prior application data; or other _____ Added the mandatory heading and subheadings for "Current Application Data". Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer. Changed the spelling of a mandatory field (the headings or subheadings), specifically: Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were: Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited: Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place. Inserted colons after headings/subheadings. Headings edited included: Deleted extra, invalid, headings used by an applicant, specifically: Deleted: non-ASCII "garbage" at the beginning end of files; secretary initials/filename at end of file;
 page numbers throughout text; other invalid text, such as _____ Inserted mandatory headings, specifically: Corrected an obvious error in the response, specifically: Edited identifiers where upper case is used but lower case is required, or vice versa. Corrected an error in the Number of Sequences field, specifically: A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted. Deleted *ending* stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____ Other:

*Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.

3/1/95

OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001

TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

3 <110> APPLICANT: The University of British Columbia; and
4 Chemokine Therapeutics Corporation
6 <120> TITLE OF INVENTION: CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS
8 <130> FILE REFERENCE: 80021-257
10 <140> CURRENT APPLICATION NUMBER: US 09/852,424
C--> 11 <141> CURRENT FILING DATE: 2001-09-26
13 <150> PRIOR APPLICATION NUMBER: CA 2,305,787
14 <151> PRIOR FILING DATE: 2000-05-09
16 <150> PRIOR APPLICATION NUMBER: US 60/205,467
17 <151> PRIOR FILING DATE: 2000-05-19
19 <160> NUMBER OF SEQ ID NOS: 135
21 <170> SOFTWARE: PatentIn Ver. 2.0
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 67
25 <212> TYPE: PRT
26 <213> ORGANISM: Artificial Sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
30 Laboratory
32 <400> SEQUENCE: 1
33 Lys Gly Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
34 1 5 10 15
36 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
37 20 25 30
39 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
40 35 40 45
42 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
43 50 55 60
45 Ala Leu Asn
46 65
49 <210> SEQ ID NO: 2
50 <211> LENGTH: 67
51 <212> TYPE: PRT
52 <213> ORGANISM: Artificial Sequence
54 <220> FEATURE:
55 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
56 Laboratory
58 <400> SEQUENCE: 2
59 Lys Gly Val Ser Pro Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
60 1 5 10 15
62 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
63 20 25 30
65 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
66 35 40 45
68 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
69 50 55 60
71 Ala Leu Asn

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001
TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

72 65
75 <210> SEQ ID NO: 3
76 <211> LENGTH: 67
77 <212> TYPE: PRT
78 <213> ORGANISM: Artificial Sequence
80 <220> FEATURE:
81 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
82 Laboratory
84 <400> SEQUENCE: 3
85 Lys Gly Val Ser Leu Pro Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
86 1 5 10 15
88 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
89 20 25 30
91 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
92 35 40 45
94 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
95 50 55 60
97 Ala Leu Asn
98 65
101 <210> SEQ ID NO: 4
102 <211> LENGTH: 67
103 <212> TYPE: PRT
104 <213> ORGANISM: Artificial Sequence
106 <220> FEATURE:
107 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
108 Laboratory
110 <400> SEQUENCE: 4
111 Lys Gly Val Ser Leu Ser Pro Arg Cys Pro Cys Arg Phe Phe Glu Ser
112 1 5 10 15
114 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
115 20 25 30
117 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
118 35 40 45
120 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
121 50 55 60
123 Ala Leu Asn
124 65
127 <210> SEQ ID NO: 5
128 <211> LENGTH: 67
129 <212> TYPE: PRT
130 <213> ORGANISM: Artificial Sequence
132 <220> FEATURE:
133 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
134 Laboratory
136 <400> SEQUENCE: 5
137 Lys Gly Val Ser Leu Ser Tyr Pro Cys Pro Cys Arg Phe Phe Glu Ser
138 1 5 10 15
140 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
141 20 25 30

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001
TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

143 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
144 35 40 45
146 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
147 50 55 60
149 Ala Leu Asn
150 65
153 <210> SEQ ID NO: 6
154 <211> LENGTH: 67
155 <212> TYPE: PRT
156 <213> ORGANISM: Artificial Sequence
158 <220> FEATURE:
159 <221> NAME/KEY: MUTAGEN
160 <222> LOCATION: (5)
161 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
162 disclosure for possible structures for P*
164 <220> FEATURE:
165 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
166 Laboratory
168 <400> SEQUENCE: 6
W--> 169 Lys Gly Val Ser Xaa Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
170 1 5 10 15
172 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
173 20 25 30
175 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
176 35 40 45
178 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
179 50 55 60
181 Ala Leu Asn
182 65
185 <210> SEQ ID NO: 7
186 <211> LENGTH: 67
187 <212> TYPE: PRT
188 <213> ORGANISM: Artificial Sequence
190 <220> FEATURE:
191 <221> NAME/KEY: MUTAGEN
192 <222> LOCATION: (6)
193 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
194 disclosure for possible structures for P*
196 <220> FEATURE:
197 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
198 Laboratory
200 <400> SEQUENCE: 7
W--> 201 Lys Gly Val Ser Leu Xaa Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
202 1 5 10 15
204 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
205 20 25 30
207 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
208 35 40 45
210 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001
TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

211 50 55 60
213 Ala Leu Asn
214 65
217 <210> SEQ ID NO: 8
218 <211> LENGTH: 67
219 <212> TYPE: PRT
220 <213> ORGANISM: Artificial Sequence
222 <220> FEATURE:
223 <221> NAME/KEY: MUTAGEN
224 <222> LOCATION: (7)
225 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
226 disclosure for possible structures for P*
228 <220> FEATURE:
229 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
230 Laboratory
232 <400> SEQUENCE: 8
W--> 233 Lys Gly Val Ser Leu Ser Xaa Arg Cys Pro Cys Arg Phe Phe Glu Ser
234 1 5 10 15
236 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
237 20 25 30
239 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
240 35 40 45
242 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
243 50 55 60
245 Ala Leu Asn
246 65
249 <210> SEQ ID NO: 9
250 <211> LENGTH: 67
251 <212> TYPE: PRT
252 <213> ORGANISM: Artificial Sequence
254 <220> FEATURE:
255 <221> NAME/KEY: MUTAGEN
256 <222> LOCATION: (8)
257 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
258 disclosure for possible structures for P*
260 <220> FEATURE:
261 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
262 Laboratory
264 <400> SEQUENCE: 9
W--> 265 Lys Gly Val Ser Leu Ser Tyr Xaa Cys Pro Cys Arg Phe Phe Glu Ser
266 1 5 10 15
268 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
269 20 25 30
271 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
272 35 40 45
274 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
275 50 55 60
277 Ala Leu Asn
278 65

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001
TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

281 <210> SEQ ID NO: 10
282 <211> LENGTH: 66
283 <212> TYPE: PRT
284 <213> ORGANISM: Artificial Sequence
286 <220> FEATURE:
287 <221> NAME/KEY: MUTAGEN
288 <222> LOCATION: (5)
289 <223> OTHER INFORMATION: Xaa=Btd=Bicyclic Turned Dipeptide. See Page 17 of
290 disclosure for possible structures for Btd
292 <220> FEATURE:
293 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
294 Laboratory
296 <400> SEQUENCE: 10

W--> 297 Lys Gly Val Ser Xaa Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser His
298 1 5 10 15
300 Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro Asn
301 20 25 30
303 Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln Val
304 35 40 45
306 Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala
307 50 55 60
309 Leu Asn
310 65

313 <210> SEQ ID NO: 11
314 <211> LENGTH: 66
315 <212> TYPE: PRT
316 <213> ORGANISM: Artificial Sequence
318 <220> FEATURE:
319 <221> NAME/KEY: MUTAGEN
320 <222> LOCATION: (6)
321 <223> OTHER INFORMATION: Xaa=Btd=Bicyclic Turned Dipeptide. See Page 17
322 of disclosure for possible structures for Btd
324 <220> FEATURE:
325 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
326 Laboratory
328 <400> SEQUENCE: 11

W--> 329 Lys Gly Val Ser Leu Xaa Arg Cys Pro Cys Arg Phe Phe Glu Ser His
330 1 5 10 15
332 Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro Asn
333 20 25 30
335 Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln Val
336 35 40 45
338 Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala
339 50 55 60
341 Leu Asn
342 65
345 <210> SEQ ID NO: 12
346 <211> LENGTH: 66
347 <212> TYPE: PRT

Use of n and / or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to ensure a corresponding explanation is present in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001
TIME: 13:56:19

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:169 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:201 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:233 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:265 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:297 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:329 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:361 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:448 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:555 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:578 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:601 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:647 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26
L:667 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:687 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:763 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:783 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:803 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:823 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:843 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:863 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:883 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:999 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44
L:1027 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45
L:1055 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46
L:1083 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47
L:1111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
L:1139 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
L:1167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
L:1189 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51
L:1230 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:53
L:1271 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:55
L:1312 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57
L:1359 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59
L:1384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60
L:1412 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:61
L:1437 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:62
L:1465 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:63
L:1490 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:64
L:1518 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:65
L:1543 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:66
L:1571 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:67
L:1596 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:68
L:1624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:69
L:1649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:70
L:1677 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:71
L:1702 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:72

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001
TIME: 13:56:19

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

L:1784 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:76
L:1809 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2024 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:86

OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/852,424

DATE: 10/10/2001

TIME: 11:17:41

Input Set : A:\80021-257.us.sequence listing.txt
 Output Set: N:\CRF3\10102001\I852424.raw

```

3 <110> APPLICANT: The University of British Columbia; and
4   Chemokine Therapeutics Corporation
6 <120> TITLE OF INVENTION: CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS
8 <130> FILE REFERENCE: 80021-257
10 <140> CURRENT APPLICATION NUMBER: US 09/852,424
C--> 11 <141> CURRENT FILING DATE: 2001-09-26
13 <150> PRIOR APPLICATION NUMBER: CA 2,305,787
14 <151> PRIOR FILING DATE: 2000-05-09
16 <150> PRIOR APPLICATION NUMBER: US 60/205,467
17 <151> PRIOR FILING DATE: 2000-05-19
19 <160> NUMBER OF SEQ ID NOS: 135
21 <170> SOFTWARE: PatentIn Ver. 2.0

```

Does Not Comply
 Corrected Diskette Needed

ERRORED SEQUENCES

```

3323 <210> SEQ ID NO: 135
3324 <211> LENGTH: 31
3325 <212> TYPE: PRT
3326 <213> ORGANISM: Artificial Sequence
3328 <220> FEATURE:
3329 <221> NAME/KEY: DOMAIN
3330 <222> LOCATION: (24)..(28)
3331 <223> OTHER INFORMATION: K28/E24 Lactamization - domain cyclized
3333 <220> FEATURE:
3334 <221> NAME/KEY: MOD_RES
3335 <222> LOCATION: (31)
3336 <223> OTHER INFORMATION: AMIDATION
3338 <220> FEATURE:
3339 <221> NAME/KEY: DOMAIN
3340 <222> LOCATION: (15)..(18)
3341 <223> OTHER INFORMATION: The number of glycines linking the N- and
3342   C-terminal amino acids may be varied.
3344 <220> FEATURE:
3345 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
3346   Laboratory
3348 <400> SEQUENCE: 135
3349 Lys Gly Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Gly Gly
3350   1           5           10          15
3352 Gly Gly Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn
3353   20          25          30
E--> 3356 59

```

*Delete miscellaneous material
 from end of file.*

Use of n and / or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to ensure a corresponding explanation is present in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/852,424

DATE: 10/10/2001
TIME: 11:17:42

Input Set : A:\80021-257.us.sequence listing.txt
Output Set: N:\CRF3\10102001\I852424.raw

L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:169 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:201 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:233 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:265 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:297 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:329 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:361 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:448 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:555 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:578 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:601 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:647 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26
L:667 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:687 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:763 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:783 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:803 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:823 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:843 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:863 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:883 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:999 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44
L:1027 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45
L:1055 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46
L:1083 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47
L:1111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
L:1139 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
L:1167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
L:1189 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51
L:1230 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:53
L:1271 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:55
L:1312 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57
L:1359 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59
L:1384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60
L:1412 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:61
L:1437 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:62
L:1465 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:63
L:1490 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:64
L:1518 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:65
L:1543 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:66
L:1571 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:67
L:1596 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:68
L:1624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:69
L:1649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:70
L:1677 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:71
L:1702 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:72

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/852,424

DATE: 10/10/2001
TIME: 11:17:42

Input Set : A:\80021-257.us.sequence listing.txt
Output Set: N:\CRF3\10102001\I852424.raw

L:1784 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:76
L:1809 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2024 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:86
L:3356 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:135